A novel combination of high-dose abatacept, ruxolitinib, and mechanical ventilation markedly improved immunotherapy-induced myocarditis survival over current guideline-recommended treatment.
Myocarditis is the most severe complication that can develop during use of immune checkpoint inhibitors, as patients present late and with at least a 50% chance of death.
Researchers at Michigan Medicine have developed a new biomarker-based technique to screen for a rare and fatal consequence caused by monoclonal antibodies, which are used to treat a variety of tumours.